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Objective: Staphylococcus aureus is one of the most significant 
pathogens causing significant morbidity and mortality. Moreover, 
the incidence of MLS S. aureus (resistant at least for one macrolide) 
infections continues to grow globally. The aim of this study is to 
examine the expression of resistance of S. aureus isolates to MLS 
and the prevalence of genes involved in this resistance using PCR.
Methods: A total 38 strains of S. aureus MLS-resistant were isolated 
in the Microbiology Labs at Nini Hospital in North Lebanon. The 
disk diffusion method was used to determine the phenotype of 
the MLS resistance. The resistance genes involved were detected 
by PCR using specific gene primers for ermA, ermB, ermC, msrA, 
linA, mefA, vat and vgb genes.
Results: A total of 55.3% of the isolates were positive for inducible 
phenotype (iMLSB), of these 15.8% were positive for the constitutive 
phenotype (cMLSB), 23.7% for MSB phenotype and 5.2% for L 
phenotype. The ermC gene was the most prevalent (52.6%), while 
ermA, ermB, msrA and linA genes were observed with lower prevalence. 
A  combination of several of these genes was detected,whereas the 
vgb, vat and mefA genes were not detected in any of the clinical 
isolates.
Conclusion: This study is the first investigated characterization of MLS 
resistance genes in clinical isolates of S. aureus in Lebanon according to 
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Introduction
Macrolides have been known for more than six 
decades, and, since the introduction of erythromy-
cin molecule into therapy, a number of these antibi-
otics have been developed for clinical use. For years, 
these drugs have represented a major alternative of 
beta-lactams for the treatment of infections caused 
by gram-positive bacteria such as ß-hemolytic Strep-
tococci, Streptococcus pneumoniae and Staphylo-
coccus aureus. Macrolides, lincosamides and strep-
togramines (MLS) are related molecules, with similar 
antibacterial spectrum and mechanisms, but with 
different chemical structure.The use of these an-
tibiotics has been accompanied by the rapid ap-
pearance of resistant strains in staphylococci [1,2].
Various resistance mechanisms have been described 
to these antimicrobials including ribosomal target 
modification by single mutation or methylation of 
23SrRNA gene, modification of the drug, and efflux 
pumps [3]. However, the predominant mechanism 
in staphylococci resistance is target modification 
mediated by ermA, ermB and ermC (erythromycin 
ribosome methylase  genes) [1,3].
Several common genes responsible for resis-
tance to macrolide, lincosamide and streptogramin 
B (MLSB) antibiotics were reported. The erm genes 
encode enzymes that confer inducible (iMLSB) or 
constitutive (cMLSB) resistance to MLSB antibiotics 
via methylation of a single adenine in the 23S rRNA 
gene, thereby reducing binding by MLSBantibiotics 
to the 50S large subunit of the ribosome [4]. An-
other fairly common mechanism of macrolide resis-
tance were reported in S. aureus and mediated by 
two important efflux genes, msrA (macrolide ef-
flux) and mefA (macrolide efflux protein A) genes, 
which confer only resistance to macrolide and strep-
togramin B (MSB) antibiotics [3,5]. The msrA gene 
encodes a 488-amino-acid ATP-binding cassette 
(ABC) transporter hydrophilic protein that contains 
two ATP-binding motifs characteristic of the ABC 
transporters. However, the mefA gene is a proton 
motive force-driven efflux pump involved in resis-
tance to MSB antibiotics [3,5,6]. Moreover, hydro-
lysis of antibiotics through the activity of esterases 
and/or phosphotransferaseshas only been reported 
in staphylococci [3].
Resistance to MLSB among S.aureus is an increasing 
problem. The overlapping binding sites of MLSB in 
23S rRNAcauses cross-resistance to the three classes 
of antibiotics. A wide range of bacterial pathogens 
that are targets for MLSBexpress Ermmethylases.The 
new nomenclature system distinguishes 21 classes 
of erm genes and as many corresponding Erm 
proteins with predominance of ermA, ermB and 
ermC in staphylococcal gene classes [2,3]. In bacterial 
pathogens, these determinants are mainly carried by 
plasmids and transposons that are self-transferable. 
The ermA gene is often harbored on the transposon 
Tn554 which has been described as predominantly 
having a single specific site for insertion in the S. 
aureus chromosome [7,8]. Furthermore, the ermB 
our knowledge. The study revealed a high prevalence of the inducible 
resistance to lincosamides (iMLSB phenotype) and the most prevalent 
resistance determinants was ermC.
Keywords: Staphylococcus aureus, Macrolides, Antimicrobial resistance, 
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gene is mostly associated on transposon Tn551 and 
the penicillinase plasmid (pI258) [9,10]. However, 
the ermC gene is normally found on small plasmids 
ranging in size from 2.4 to 5 kb [4].
Other resistance mechanisms to MLS were 
reported. The O-nucleotidyltransferases encoded in 
S. aureus by lincosamide inactivation nucleotidylation 
(lin)genes, confer resistance to lincomycin but not to 
clindamycin (L phenotype)[1,11,12]. The staphylococcal 
vat genes confer resistance to streptogramin A and 
similar compounds by acetylation of the antibiotics. 
In addition, the staphylococcal vga genes encode 
related ATP-binding proteins probably involved in the 
active efflux of A compounds [13,14].
This study aimed to  investigate the epidemiology 
of MLS resistance in Lebanon, particularly   preva-
lence of MLS resistance phenotypes and molecu-
larly characterize the macrolide resistance genes in 




Thirty-eightS. aureus MLS-resistant isolates were 
collected from patients in Nini hospital. All isolates 
were transported immediately to the Health and 
Environmental Microbiology Laboratory strain bank, 
in theAZM center for research in biotechnology, 
doctoral school, Lebanese University in Tripoli.
Antimicrobial susceptibility test
The susceptibility to antibiotics was performed 
by the disk diffusion method on Muller-Hinton agar 
(Bio-Rad, France) according to CLSI (Clinical and 
Laboratory Standards Institute) and CA-SFM 2015 
(Comité de l’Antibiogramme de la SociétéFrançaise 
de Microbiologie 2015) recommendations. 
MLS resistance phenotypes were performed using 
D-test with the following antibiotics: Erythromycin 
(15UI), lincomycin (15 µg),spiramycin (100μg) and 
pristinamycin (15μg).
DNA extraction and molecular 
identification of resistance genes 
All S. aureus strains were tested for detection 
of macrolide resistance genes. DNA was extracted 
using the GenElute™ Bacterial Genomic DNA (Sigma 
Aldrich®,England), according to the manufacturer’s 
recommended procedures. The DNA was eluted in 
200 μl of elution buffer and stored at -20°C until 
use. All genes known to be responsible for S.aureus 
resistance to beta-lactams (mecA) and MLS (ermA, 
ermB, ermC, msrA, mefA, vat, vgb, and linA genes) 
were detected using  PCR   and primers specific to 
each gene (Table 1). Purified bacterial DNA from 
control strains and deionized water were respectively 
used as positive and negative control in each PCR run.
Statistical analyses
Statistical analyses were performed with 
GraphPad Prism 6.0 (GraphPad Software Inc., San 
Diego, CA) using the Fisher’s exact test to explore 
the association between resistance to MLS and 
resistance to beta-lactams. The general significance 
level was set at a P-value below 0.05.
Results 
The percentage of susceptibility of all S.aureus 
isolates is showed in Table 2. Resistance to beta-
lactams was found in 28/ 38 (73.7%) strains using 
the disk diffusion method and PCR targeting mecA 
gene. MLS resistance phenotypes were determined 
by with D-test showed that among 38MLS-resistant 
isolates, 27 (71.1%) exhibited the MLSB phenotype: 6 
(15.8%) belonged to the cMLSB, and 21 (55.3%) to 
the iMLSB phenotype. The remaining 11 isolates (28.9 
%) were confirmed as MSB (23.7%) and L (5.2%) 
phenotypes (Table 3). No significant association 
between resistance to MLS and resistance to beta-
lactams was found (Fisher’s exact test, p-value = 0.6).
In addition, PCR analysis targeting macrolide 
resistance genes showed that all iMLSB and cMLSB 
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strains harbored at least the ermC gene, exceptthree 
iMLSB isolates that did not carry any of the tested 
genes.The MSB isolates carried ermA gene (1/9),mrsA 
gene (5/9), both ermA and ermC genes (1/9) and 
both ermC and mrsA genes (2/9). The two L isolates 
carried linA and both linA and mrsA respectively.On 
the other hand, mefA, vat andvgb genes were not 
detected in any of the isolates (Table 4).
Table 1. Primers and PCR conditions used to detect the resistance genes.










190 [16] 30 cycles (30 s at 94°C; 30 s at 52°C; 1 
min at 72°C) ; 
ermB F. CTATCTGATTGTTGAAGAAGGATT
R. GTTTACTCTTGGTTTAGGATGAAA
142 [16] Same as ermA
ermC F. AATCGTCAATTCCTGCATGT
R. TAATCGTGGAATACGGGTTTG
299 [16] Same as ermA
linA F. GGTGGCTGGGGGGTAGATGTATTAACTGG
R. GCTTCTTTTGAAATACATGGTATTTTTCGATC
323 [17] 30 cycles (30 s at 94°C; 30 s at 57°C; 1 
min at 72°C) ; 
Vat F. CAATGACCATGGACCTGATC
R. CTTCAGCATTTCGATATCTCC
619 [16] Same as ermA
Vgb F. ACTAACCAAGATACAGGACC
R. TTATTGCTTGTCAGCCTTCC
734 [17] 30 cycles (1 min at 94°C; 1 min at 53°C; 
2 min at 72°C) ; 
msrA F. GGCACAATAAGAGTGTTTAAAGG
R. AAGTTATATCATGAATAGATTGTCCTGTT
940 [17] 25 cycles (1 min at 94°C; 1 min at 50°C; 
90 s at 72°C) ; 
mefA F. AGTATCATTAATCACTAGTGC
R. TTCTTCTGGTACTAAAAGTGG
348 [18] 35 cycles (30 s at 94°C; 30 s at 50°C; 90 
s at 72°C) ; 





% of  
susceptible
Fusidic acid (10 µg) 76.3% Novobiocin (5 µg) 89.2%
Amoxicillin/clavulanic acid
(20/10 µg)
26.3% Oxacillin (5 µg) 26.3%
Cefoxitin (30 µg) 26.3% Ciprofloxacin (5 µg) 34.2%
Chloramphenicol (30 µg) 94.7% Pristinamycin (15 µg) 97.4%
Erythromycin (15 µg) 5.2% Rifampicin (30 µg) 94.6%
Fosfomycin (50 µg) 92.1% Spiramycin (100 µg) 57.9%
Gentamicin (15 µg) 78.9% Teicoplanin (30 µg) 100%
Kanamycin (30 µg) 71.1% Tetracycline (30 µg) 78.9%
Lincomycin (15 µg) 76.3% Tigecycline (15 µg) 97.4%
Linézolid (30 µg) 100% Tobramycin (10 µg) 76.3%
Minocycline (30 µg) 97.3% Trimethoprim/sulfamethoxazole (1,25/23,75 µg) 81.6%
Nitrofuran (300 µg) 100% Vancomycin (30 µg) 100%
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Discussion
The resistance to antibiotics among S. aureus 
is an increasing problem, both in hospitals and 
communities of  most Arab Middle East countries. 
A recent review by Tokajian et al. [19] on the 
epidemiology of S. aureus in these countries showed 
wide genetic change due to the introduction of 
new clones from other countries. Moreover, a 
previous study conducted in the same geographic 
region, demonstrated that methicilli-nresistant S. 
aureus (MRSA) strains colonizing infants carried 
1-3 clinically important staphylococcal toxin genes 
[20]. In Lebanon, a recent study on antimicrobial 
susceptibility patterns of S. aureus clinical isolates 
revealed that only 56% were susceptible to all 
tested antibiotics [21]. In addition, the prevalence 
of MRSA infection are also increased in Lebanon 
in the last decade [22,23].These reports have led 
to renewed interest in the usage of MLS to treat 
staphylococcal  infections [24]. Clindamycin is now a 
good alternative in the treatment of infections due 
to S. aureus, particularly MRSA isolates and as an 
alternative in penicillin-allergic patients. However, 
clindamycin resistance can be developed rapidly in 
S. aureus strains, and constitutive resistant mutants 
have arisen both in vitro testing and in vivo clinical 
therapy [25,26].
The CLSI and CA-SFM 2015 guidelines for disk 
diffusion susceptibility recommend the use of D-test 
to detect the inducible clindamycin resistance (iMLSB 
phenotype),and suggest that S. aureus isolates 
with the iMLSB phenotype should be reported 
as clindamycin-susceptible, but associated with 
clinical failures possibility related to the selection of 
clindamycin-resistant mutants.
A total of 38 S. aureus clinical isolates 
were examined. Firstly, according to the D-test 
screening, the iMLSB phenotype was the most 
predominant resistant phenotype (55.3%). These 
findings were different from the results obtained 
in a study conducted amongS. aureus isolates in 
Turkey, whereby the cMLSB phenotype was the 
predominant resistance phenotype (63%) [27]. 
Otherwise, we reported a similar distribution of 
MLS resistance phenotypes to that described in the 
UK by Hamilton-Miller et al.[28]. However, various 
studies conducted in Turkey [27], Europe [29], Japan 
Table 3. The MLS phenotypes of resistance detected for S. aureus isolates.
Phenotype iMLSB (%) cMLSB (%) MSB (%) L (%) Total no. (%)
MRSA 16 (42.1%) 5 (13.2%) 5 (13.2%) 2 (5.2%) 28 (73.7%)
MSSA 5 (13.2%) 1 (2.6%) 4 (10.5%) 0 (0%) 10 (26.3%)
Total 21 (55.3%) 6 (15.8%) 9 (23.7%) 2 (5.2%) 38 (100%)
















iMLSB 0 15 1 1 1 0 0 0 0 3
cMLSB 0 5 0 1a 0 0 0 0 0 0
MSB 1 0 0 1 0 2 5 0 0 0
L 0 0 0 0 0 0 0 1 1 0
aPristinamycin-resistant strain ; No.I  was non-identified genotype.
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[30]Colombia [31], and France [17], reported that the 
iMLSB and cMLSB phenotypes were predominant in 
methicillin-susceptible S. aureus (MSSA) and MRSA 
isolates, respectively. However, may be due to the 
low number of examined S. aureus strains in this 
study, we could not find any association between 
MLSresistance phenotypes and resistance to beta-
lactams.
Secondly, it has reported that accurate and rapid 
determination of antimicrobial resistance genes will 
help to select the proper the treatment of S. aureus 
infections and to avoide the spread of resistant 
genes [32,33]. Overall, 36 / 38 of the examined 
strains were resistant to erythromycin, of these, 
91.6%  had at least one of these genes:ermA, ermB, 
ermC and/ormsrA. These results are similar to those 
reported by Martinau et al. [34]  who demonstrated 
the same findings among S. aureus strains resistant 
to erythromycin. However,  3 of those isolates did 
not carry any of the tested genes.These results were 
probably associated with the presence of other 
genes with low frequency in S. aureus, which were 
not evaluated in our investigation [33]. Also, this 
study found that efflux genes such as msrA gene 
was present either alone or in association with other 
genes (23.7%), while the mefA gene was absent 
from all tested isolates. These results concur with 
those described by Zmantar et al.  [35], who reported 
the same observation. Furthermore, we found a 
predominance of ermC gene (27/38) among MLS 
resistance genes. The ermC gene was described 
to be the predominant MLS resistance gene in S. 
aureus isolates in Greece [36]. On the other hand, 
the ermA gene was detected alone in one isolate, 
and in association with ermC gene in 3 isolates of 
S. aureus, while a Colombian investigation reported 
that 100% of MRSA resistant to erythromycin had 
the cMLSB resistance phenotype and harbored the 
ermA gene [31]. In the same context, recent data 
from a multicenter study in Europe confirmed the 
predominance of ermA gene among S. aureus, 
while ermC and ermB genes were rarely detected 
[37]. Additionally, two isolates in our study harbored 
the linA gene.  These results are also supported by 
recent findings, which showed that the linA gene 
was rarely detected in S. aureus strains [17,38,39].
Finally, all tested S. aureus strains, including 
methicillin resistant and MLS-resistant  were 
susceptible to linezolid and vancomycin. Our data 
accord with a previous study conducted by Kanj et al. 
[40], in which good activity of these antibiotics was 
described against most Gram-positive pathogens 
from the Middle East and Africa.
In conclusion, to our best knowledge, this study is 
the first investigation regarding characterization of 
MLS resistance genes in clinical isolates of S. aureus 
in Lebanon. Our data indicates a predominance of 
iMLSB phenotype and ermC gene in these isolates. 
Other genes  ( ermA, ermB, msrA and linA) were 
found  with lower prevalence.  The epidemiological 
significance of this study remains to be confirmed 
by further testing large number of S. aureus strains. 
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